RGNX Similar Chart Price Prediction
The price of RGNX is predicted to go up 0.67%, based on the high correlation periods with SANM. The similarity of these two price pattern on the periods is 97.63%.
RGNX
SANM
Up: 0.67%Similarity: 97.63%
RGNX Revenue Forecast
RGNX EPS Forecast
RGNX FAQs
What is RGNX revenue forecast for next quarter？
RGNX Analyst's Forecast
Paul Choi
Goldman Sachs
Strong Buy → Hold
2025-02-11
Price Target
$38 → $14
Upside
+91%
Goldman Sachs downgraded Regenxbio to Neutral from Buy with a price target of $14, down from $38. The firm has questions over the ultimate appeal of gene therapy in wet age-related macular degeneration given the largely elderly patient population and increasing injection-free period of existing anti-VEGF therapy, which it says offer significantly more favorable pricing. Goldman also sees "waning differentiation" for Regenxbio versus competitor programs given the invasive administration methods used for ABBV-RGX-314.
Judah Frommer
Morgan Stanley
Buy
2024-11-15
Price Target
$22
Upside
+128.45%
Danielle Brill
Raymond James
Buy
2024-10-10
Price Target
$18
Upside
+93.76%
